ASPIRA WOMEN'S HEALTH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.07 USD | +3.02% |
|
-4.45% | -24.75% |
Presentation Operator MessageOperator (Operator)Greetings, ladies and gentlemen. Good afternoo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.
Calendar
2024-05-13
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.98
USD
Average target price
5.25
USD
Spread / Average Target
+76.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.75% | 36.8M | |
| -26.80% | 10.94B | |
| +65.44% | 3.75B | |
| -28.13% | 2.27B | |
| -10.06% | 2.25B | |
| -25.01% | 1.54B | |
| +50.53% | 1.18B | |
| -2.84% | 754M | |
| -7.83% | 529M | |
| -27.35% | 469M |
- Stock Market
- Equities
- AWH Stock
- News Aspira Women's Health Inc.
- Transcript : Aspira Women's Health Inc., Q3 2020 Earnings Call, Nov 12, 2020